Ahmad Masri

🎉 Congrats to the first ARC #ClinicalFellowship awardees! Thank you for helping shape the next generation of #amyloidosis experts. Together, we're building a brighter future for patients. 💙 Learn more: arci.org/fellowship/

Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance CMR with ECV mapping can track changes in cardiac amyloid burden and treatment response in ATTR-CM, with changes in ECV being independently associated with…

Diagnostic yield in families to sudden cardiac death victims: a 10-year follow-up study Long-term follow-up identified an inherited heart disease in 12% of SCD relatives, primarily diagnosed within 5 years. Cardiac events were rare (4%). These findings suggest that follow-up may…

Seek and you shall find: red flags in hypertrophic phenotypes Clinical red flags in patients presenting with HCM are effective in screening for HCM phenocopies and should be systematically implemented in both generalist and specialty practices academic.oup.com/eurheartj/adva…

If you're applying for Nephrology fellowship let @DGlaucomflecken tell you why you need to apply to @OHSUNephrology. Then let us tell you all the reasons why its such a great training program! #nephtwitter

🧵Check out our work @JAHA_AHA on 3-year outcomes following septal myectomy in 5,300 obstructive HCM patients. High overall burden of CVH post-myectomy in this unselected HCM cohort from wide range of practices. AFib/flutter is major issues! 25% develop new AF/AFL within 1st…

In this #JACCBTS article, authors demonstrate that repetitive pressure overload in swine develops interstitial fibrosis and chamber stiffening that persists up to 4 weeks. jacc.org/doi/10.1016/j.… #HFpEF

Targeting the underlying precursor protein is simpler than removing amyloid. Pathophysiology of AL is complex, and having different involved light chains as well makes it harder to develop a singular therapy. I am encouraged by the mention of a specific group that derived…

If you image amyloid or take care of patients at risk An important document by @MyASNC sciencedirect.com/science/articl… #Cardiotwitter #CVNuc

Left atrial size trajectories and outcome over a 35-year follow-up in patients with hypertrophic cardiomyopathy sciencedirect.com/science/articl… @ElsevierConnect

CVH post myectomy. Over a 3 year follow up. Significant burden overall for this unselected population from wide range of practices. Events significantly decrease after the first 1.5 years. AF is a major issue Great work by @Teebi_MD ahajournals.org/doi/10.1161/JA… #CardioTwitter

Five Studies We Are Looking For Ward in Heart Failure to at ESC 2025 Madrid Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics Beta-blockers remain first-line therapy for symptomatic oHCM despite…

Interesting paper on outcomes of ARVC vs exercise induced phenotype jacc.org/doi/epdf/10.10… Structure remains stable in exercise induced phenotype while arrhythmia occurrence was similar #cardiotwitter

What’s new in #cvImaging of cardiac #amyloidosis? 124I-evuzamitide PET-CT can identify variant transthyretin allele carriers & wild-type subjects when 99mTc-pyrophosphate does not. jacc.org/doi/10.1016/j.… #cvNuc #JACCIMG #cvPET #ATTR @timpotsMD @AniNalbandian1

1/43 Welcome to this MedX CME on transthyretin amyloid cardiomyopathy (ATTR-CM), including updates in treatment from ACC25, with cardiologist Michelle Kittleson, MD, PhD. Earn credit: link.med-iq.com/57jSxO

ESC Congress LBT announced today! Delighted to present the results of the MAPLE-HCM trial in my hometown of MADRID! 🎉👏🏻🥳 Aficamten vs BB in monotherapy for obstructive HCM 🤔 Saturday 30th in Hot line session 2! Stay tunned!! ⏱️ @CNIC_CARDIO @cardiopdh @Cytokinetics

🔔 We’ve extended the abstract submission deadline to August 4! There’s still time to share your work & insights with top international experts. 📢 Easy submission guidelines here: 🌐 hypertrophiccardiomyopathyacoruna.com/abstracts/